Audentes Therapeutics Inc (NASDAQ:BOLD) shot up 9.5% on Tuesday . The stock traded as high as $28.30 and last traded at $27.98, 418,400 shares were traded during trading. A decline of 14% from the average session volume of 486,658 shares. The stock had previously closed at $25.55.

Several brokerages recently weighed in on BOLD. Robert W. Baird began coverage on Audentes Therapeutics in a report on Wednesday, October 2nd. They set an “underperform” rating and a $10.00 price target for the company. William Blair reaffirmed a “hold” rating on shares of Audentes Therapeutics in a report on Wednesday, August 7th. ValuEngine downgraded Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Chardan Capital reaffirmed a “buy” rating and set a $50.00 price target on shares of Audentes Therapeutics in a report on Sunday, October 6th. Finally, Zacks Investment Research downgraded Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $40.71.

The company has a 50-day simple moving average of $27.52 and a 200-day simple moving average of $33.61. The stock has a market cap of $1.18 billion, a PE ratio of -8.28 and a beta of 1.77.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.07) by $0.07. During the same period in the previous year, the firm posted ($0.97) earnings per share. As a group, equities research analysts forecast that Audentes Therapeutics Inc will post -4.13 earnings per share for the current fiscal year.

In other Audentes Therapeutics news, Director Louis G. Lange sold 10,000 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $32.16, for a total value of $321,600.00. Following the completion of the transaction, the director now owns 276,044 shares in the company, valued at $8,877,575.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Matthew R. Patterson sold 14,426 shares of the firm’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $30.00, for a total value of $432,780.00. Following the completion of the transaction, the chief executive officer now owns 127,820 shares of the company’s stock, valued at approximately $3,834,600. The disclosure for this sale can be found here. Corporate insiders own 5.30% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of Audentes Therapeutics by 14.2% in the second quarter. BlackRock Inc. now owns 3,333,445 shares of the biotechnology company’s stock valued at $126,204,000 after buying an additional 413,768 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Audentes Therapeutics by 4.5% in the second quarter. Vanguard Group Inc. now owns 1,971,206 shares of the biotechnology company’s stock valued at $74,629,000 after buying an additional 84,659 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of Audentes Therapeutics by 2.7% in the second quarter. Victory Capital Management Inc. now owns 904,221 shares of the biotechnology company’s stock valued at $34,233,000 after buying an additional 23,620 shares in the last quarter. D. E. Shaw & Co. Inc. increased its position in shares of Audentes Therapeutics by 118.6% in the second quarter. D. E. Shaw & Co. Inc. now owns 592,947 shares of the biotechnology company’s stock valued at $22,449,000 after buying an additional 321,756 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Audentes Therapeutics by 3.1% in the second quarter. Northern Trust Corp now owns 454,949 shares of the biotechnology company’s stock valued at $17,224,000 after buying an additional 13,685 shares in the last quarter. Institutional investors and hedge funds own 99.39% of the company’s stock.

About Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Story: What is a Call Option?

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.